Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort Study.
Ahmad AlbsheshLian BannonTali Sharar FischlerMarie TruyensStephan R VavrickaKatja TepesDaniela PuglieseEdoardo Vincenzo SavarinoEran ZittanDavid DrobneXavier RoblinAriella Bar-Gil ShitritAlessandro ArmuzziTriana LobatonNitsan MaharshakHenit YanaiShomron Ben-HorinUri KopylovPublished in: Journal of clinical medicine (2023)
Second-line biological therapy after VDZ failure therapy was effective in >60% of the patients with CD. No differences in effectiveness were detected between the use of anti-TNF and UST as a second line.